| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Co-Diagnostics (NASDAQ:CODX) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17...
Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a patented ...
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, ...
-SEC Filing